| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790197 | Urologic Oncology: Seminars and Original Investigations | 2018 | 6 Pages |
Abstract
Patients with mRCC who progress on 50Â mg sunitinib dose, may derive a clinical benefit and prolonged survival from dose-escalation with acceptable toxicity profiles. These results need to be confirmed in prospective studies with the aim to overcome drug resistance and delay the change in systemic therapy at progression.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jacques M.D., M.Sc., Alia PharmD, Georg A. M.D.,